- Joined
- Apr 16, 2004
- Messages
- 4,661
- Reaction score
- 5,080
Since we had such a great discussion about prostate hypofractionation, I thought we could go over another controversial topic.
David Raben gave an excellent presentation to our residents last year on dose reduction (perhaps to 60 Gy or so with a single cycle of CDDP) for p16 positive oropharyngeal SCC. Logically it makes good sense due to Ang's retrospective finding of better prognosis in these patients.
I'm wondering if any of your institutions are enrolling patients on Phase I/II studies.
I recently had a patient with T2 N1 right tonsil cancer who I felt kind of guilty about going to the standard 70 Gy + 2 cycles CDDP because this was likely over-treatment. Sadly I had no data to proceed otherwise.
David Raben gave an excellent presentation to our residents last year on dose reduction (perhaps to 60 Gy or so with a single cycle of CDDP) for p16 positive oropharyngeal SCC. Logically it makes good sense due to Ang's retrospective finding of better prognosis in these patients.
I'm wondering if any of your institutions are enrolling patients on Phase I/II studies.
I recently had a patient with T2 N1 right tonsil cancer who I felt kind of guilty about going to the standard 70 Gy + 2 cycles CDDP because this was likely over-treatment. Sadly I had no data to proceed otherwise.